IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells

被引:49
|
作者
Shi, Ping [1 ]
Lai, Raymond [2 ]
Lin, Quan [1 ]
Iqbal, Abid S. [1 ]
Young, Leah C. [3 ]
Kwak, Larry W. [4 ]
Ford, Richard J. [1 ]
Amin, Hesham M. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[2] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada
[3] Univ Alberta, Dept Med Genet, Edmonton, AB, Canada
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
GROWTH-FACTOR-I; BREAST-CANCER CELLS; FACTOR RECEPTOR; CYCLOLIGNAN PPP; MULTIPLE-MYELOMA; INSULIN-RECEPTOR; PROSTATE-CANCER; FRENCH SOCIETY; ANTISENSE RNA; CYCLE ARREST;
D O I
10.1182/blood-2007-11-125658
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type I insulin-like growth factor receptor (IGF-IR) tyrosine kinase plays important roles in the pathogenesis of several malignancies. Although it promotes the growth of stimulated hematopoietic cells, a direct role of IGF-IR in malignant lymphoma has not been identified. Anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK(+) ALCL) is a unique type of T-cell lymphoma. Approximately 85% of ALK(+) ALCL cases harbor the translocation t(2; 5)(p23;q35), which generates the chimeric oncogene NPM-ALK. In the present study, we explored a possible role of IGF-IR in ALK(+) ALCL. Our results demonstrate that IGF-IR and IGF-I are widely expressed in ALK(+) ALCL cell lines and primary tumors. Importantly, we identified novel reciprocal functional interactions between IGF-IR and NPM-ALK. Antagonism of IGF-IR decreased the viability, induced apoptosis and cell-cycle arrest, and decreased proliferation and colony formation of ALK(+) ALCL cell lines. These effects could be explained by alterations of cell survival regulatory proteins downstream of IGF-IR signaling. Our findings improve current understanding of the biology of IGF-IR and NPM-ALK and have significant therapeutic implications as they identify IGF-IR signaling as a potential therapeutic target in ALK(+) ALCL and possibly other types of malignant lymphoma. (Blood. 2009; 114: 360-370)
引用
收藏
页码:360 / 370
页数:11
相关论文
共 50 条
  • [21] NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a
    Gu, TL
    Tothova, Z
    Scheijen, B
    Griffin, JD
    Gilliland, DG
    Sternberg, DW
    BLOOD, 2004, 103 (12) : 4622 - 4629
  • [22] MKK4 and MKK7 Interact with NPM-ALK and Contribute to Tumor Cell Proliferation and Survival in NPM-ALK plus Anaplastic Large Cell Lymphoma
    Rassidakis, G.
    Georgoulis, P.
    Atsaves, V.
    Tsioli, P.
    Drakos, E.
    Medeiros, L. J.
    Panayiotidis, P.
    Patsouris, E.
    LABORATORY INVESTIGATION, 2010, 90 : 318A - 318A
  • [23] The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration
    Voena, Claudia
    Conte, Chiara
    Ambrogio, Chiara
    Erba, Elisabetta Boeri
    Boccalatte, Francesco
    Mohammed, Shabaz
    Jensen, Ole N.
    Palestro, Giorgio
    Inghirami, Giorgio
    Chiarle, Roberto
    CANCER RESEARCH, 2007, 67 (09) : 4278 - 4286
  • [24] NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells
    Ambrogio, Chiara
    Martinengo, Cinzia
    Voena, Claudia
    Tondat, Fabrizio
    Riera, Ludovica
    di Celle, Paola Francia
    Inghirami, Giorgio
    Chiarle, Roberto
    CANCER RESEARCH, 2009, 69 (22) : 8611 - 8619
  • [25] DETECTION OF NPM-ALK DNA REARRANGEMENT IN CD30 POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMA
    WAGGOTT, W
    LO, YMD
    BASTARD, C
    GATTER, KC
    LEROUX, D
    MASON, DY
    BOULTWOOD, J
    WAINSCOAT, JS
    BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (04) : 905 - 907
  • [26] MKK4 and MKK7 Interact with NPM-ALK and Contribute to Tumor Cell Proliferation and Survival in NPM-ALK plus Anaplastic Large Cell Lymphoma
    Rassidakis, G.
    Georgoulis, P.
    Atsaves, V.
    Tsioli, P.
    Drakos, E.
    Medeiros, L. J.
    Panayiotidis, P.
    Patsouris, E.
    MODERN PATHOLOGY, 2010, 23 : 318A - 318A
  • [27] Small-cell variant of ALK+ anaplastic large-cell lymphoma with a leukemic phase
    不详
    BLOOD, 2014, 124 (20) : 3175 - 3175
  • [28] The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
    George, Suraj Konnath
    Vishwamitra, Deeksha
    Manshouri, Roxsan
    Shi, Ping
    Amin, Hesham M.
    ONCOTARGET, 2014, 5 (14) : 5750 - 5763
  • [29] Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma
    Pulford, K
    Falini, B
    Banham, AH
    Codrington, D
    Roberton, H
    Hatton, C
    Mason, DY
    BLOOD, 2000, 96 (04) : 1605 - 1607
  • [30] Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma
    Armanious, Hanan
    Gelebart, Pascal
    Anand, Mona
    Lai, Raymond
    CELLULAR SIGNALLING, 2013, 25 (02) : 381 - 388